Trial Profile
A Phase 2, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Standard of Care in Subjects With Previously Untreated and Advanced (Unresectable or Metastatic) Non-clear Cell Renal Cell Carcinoma (nccRCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SUNIFORECAST
- 10 Apr 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been completed in France, according to European Clinical Trials Database.
- 16 Feb 2024 This trial has been completed in Czechia, according to European Clinical Trials Database.